SCHEMBL332254

SCHEMBL332254

CC(Cc1ccc(-c2ccccc2)cc1)O[C]=O

nearest known ligand 0.46

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
SRR Q9GZT4 2/20 0.46
PSAT1 Q9Y617 2/20 0.46
ACACB O00763 1/20 0.46
PPARG P37231 8/20 0.45
PPARA Q07869 6/20 0.45
MME P08473 6/20 0.44
ACE P12821 6/20 0.44
CPA1 P15085 2/20 0.44
ACE2 Q9BYF1 2/20 0.44
ACP3 P15309 1/20 0.42
FFAR1 O14842 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3678018 0.89 TAAR1 (0.48)
SCHEMBL11342602 0.81 ACACB (0.41) ACACBPPARGPPARAFFAR1
SCHEMBL10590307 0.81 MAPT (0.40) PPARGPPARA
SCHEMBL6493977 0.78 KMT2A (0.51) PPARGPPARAMMEACECPA1
SCHEMBL11504701 0.78 ACACB (0.48) SRRPSAT1ACACBPPARGPPARA
SCHEMBL332255 0.76 SRR (0.47) SRRPSAT1ACACBPPARGPPARA
SCHEMBL11082685 0.76 CYP19A1 (0.42) ACACB
SCHEMBL6141386 0.76 PPARA (0.43) PPARGPPARAMMEACECPA1
SCHEMBL1335887 0.74 TAAR1 (0.50) SRRPSAT1MMEACECPA1
SCHEMBL14332190 0.74 PTGS2 (0.48) ACACBACP3FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 470 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114585615-A Synthesis of 6-methyl-N1- (4- (pyridin-3-yl) pyrimidin-2-yl) benzene-1, 3-diamine 新加坡艺思高艾斯特生物科技有限公司 2022-06-03 CN claimed
CN-108218903-B Process for the preparation of L-BPA 南京中硼联康医疗科技有限公司 2020-12-08 CN claimed
CN-111770928-A Synthesis of oligonucleotides and nucleic acids 埃万奈蒂克有限公司 2020-10-13 CN claimed
CN-108373479-B Process for the preparation of L-BPA 南京中硼联康医疗科技有限公司 2020-06-12 CN claimed
US-9822146-B2 Process for the manufacture of degarelix and its intermediates FERRING B.V. (NL) 2017-11-21 US claimed
US-20160145301-A1 PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES FERRING BV (NL) 2016-05-26 US claimed
EP-2161277-B1 Asymmetric synthesis of peptides UNIV READING (GB) 2013-04-10 EP claimed
US-8399612-B2 Asymmetric synthesis of peptides UNIVERSITY OF READING (GB) 2013-03-19 US claimed
US-20120190816-A9 ASYMMETRIC SYNTHESIS OF PEPTIDES UNIVERSITY OF READING 2012-07-26 US claimed
US-20110275784-A1 ASYMMETRIC SYNTHESIS OF PEPTIDES UNIVERSITY OF READING 2011-11-10 US claimed
EP-1922345-A2 PROCESS FOR THE PREPARATION OF COPOLYMER-1 Chan, Wai Hong (US) 2008-05-21 EP claimed
US-20070141663-A1 Process for the preparation of copolymer-1 DING JINGUO 2007-06-21 US claimed
US-7232923-B2 Method of hydroaminating N-alkenoylcarbamates with primary aromatic amines IMPERIAL INNOVATIONS LIMITED (GB) 2007-06-19 US claimed
WO-2007031698-A1 ASYMMETRIC SYNTHESIS OF PEPTIDES UNIVERSITY OF READING (GB) 2007-03-22 WO claimed
WO-2007022193-A2 PROCESS FOR THE PREPARATION OF COPOLYMER-1 CHAN WAI HONG (US) 2007-02-22 WO claimed
US-20060183933-A1 Method of hydroaminating N-alkenoylcarbamates with primary aromatic amines IMPERIAL COLLEGE INNOVATION LIMITED (GB) 2006-08-17 US claimed
WO-2004013139-A2 PROCESS FOR PREPARING 7-AZAINDOLES EISAI CO., LTD (JP) 2004-02-12 WO claimed
EP-0053540-B1 CEPHALOSPORIN DERIVATIVES AND THEIR PREPARATION RHONE-POULENC SANTE (FR) 1985-08-14 EP claimed
EP-0053540-A1 Cephalosporin derivatives and their preparation RHONE-POULENC SANTE (FR) 1982-06-09 EP claimed
US-3944590-A ALKYL PHENYL CARBONATES CIBA-GEIGY CORPORATION (US) 1976-03-16 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275784-A1 ASYMMETRIC SYNTHESIS OF PEPTIDES PTMS, NGLY1, QPCT SRR 32/4885PSAT1 1115/4885ACACB 3299/4885
US-20160145301-A1 PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES VIP, HABP2, DPP9 SRR 1740/4885PSAT1 3757/4885ACACB 3678/4885
US-20120190816-A9 ASYMMETRIC SYNTHESIS OF PEPTIDES PTMS, NGLY1, QPCT SRR 32/4885PSAT1 1115/4885ACACB 3299/4885
US-20060183933-A1 Method of hydroaminating N-alkenoylcarbamates with primary aromatic amines ALKBH3, HNMT, ALKBH1 SRR 4097/4885PSAT1 2767/4885ACACB 610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.